Baidu
map

药械

订阅

MedSci主页 / 所有栏目 / 药械

Chemistry & Biology ：靶向Exportin-1的新型抗癌药

2015-03-06 佚名 生物谷

抗癌药靶向治疗
关注

  一项最新研究发现：基因修饰的癌细胞可以澄清新癌症药物的作用机制。在人类细胞中，细胞核含​​有我们的DNA，并作为一个“控制中心”，而细胞质充当细胞的“体”。正是在这里，蛋白质得以生成和回收。 但是否蛋白质有活性或无活性依赖于它在细胞中的位置。细胞使用运输系统，以确保蛋白质达到需要它的部位。在健康的细胞中，蛋白质不断地在细胞核和细胞质之间被输送。 在各转运蛋白的协助下，运输进出细

 

一项最新研究发现：基因修饰的癌细胞可以澄清新癌症药物的作用机制。在人类细胞中，细胞核含​​有我们的DNA，并作为一个“控制中心”，而细胞质充当细胞的“体”。正是在这里，蛋白质得以生成和回收。

但是否蛋白质有活性或无活性依赖于它在细胞中的位置。细胞使用运输系统，以确保蛋白质达到需要它的部位。在健康的细胞中，蛋白质不断地在细胞核和细胞质之间被输送。

在各转运蛋白的协助下，运输进出细胞核。当中最知名的是Exportin-1，其运输超过200种不同的蛋白质。Exportin-1的“乘客”之一是肿瘤抑制蛋白。当在细胞核中，这些蛋白质能够检测受损的DNA，并触发细胞死亡。但某些癌细胞通过输送抗癌蛋白出细胞核并进入细胞质，扰乱Exportin-1的正常运转，在那里它们执行癌症抑制的工作被防止。

Rega Institute和Department of Chemistry研究人员先前报告了Exportin-1的抑制剂。 Karyopharm Therapeutics公司专注于发现和开发针对核运输靶标的新型药物，已确定并开发了Exportin-1抑制剂KPT-330用于治疗癌症。在这项新研究中，研究人员证实KPT-330能够靶向并阻断Exportin-1。分子KPT-330能连接到一个特定的氨基酸（Exportin-1蛋白质的结构单元）。

原始出处

Jasper E. Neggers,  et al.Identifying Drug-Target Selectivity of Small-Molecule CRM1/XPO1 Inhibitors by CRISPR/Cas9 Genome Editing.Chemistry & Biology.2015

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1783004, encodeId=8fc71e8300410, content=<a href='/topic/show?id=854546080a' target=_blank style='color:#2F92EE;'>#chemistry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4608, encryptionId=854546080a, topicName=chemistry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Tue Oct 27 06:45:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785933, encodeId=29f11e8593335, content=<a href='/topic/show?id=64fbe169a5' target=_blank style='color:#2F92EE;'>#export#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7169, encryptionId=64fbe169a5, topicName=export)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Mon Aug 24 12:45:00 CST 2015, time=2015-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917134, encodeId=ca12191e1348a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Feb 14 09:45:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766932, encodeId=4d7d1e669322d, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Mon Sep 28 10:45:00 CST 2015, time=2015-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314625, encodeId=4ed01314625ad, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Mar 08 00:45:00 CST 2015, time=2015-03-08, status=1, ipAttribution=)]
    2015-10-27 kzlchina

    #chemistry#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1783004, encodeId=8fc71e8300410, content=<a href='/topic/show?id=854546080a' target=_blank style='color:#2F92EE;'>#chemistry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4608, encryptionId=854546080a, topicName=chemistry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Tue Oct 27 06:45:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785933, encodeId=29f11e8593335, content=<a href='/topic/show?id=64fbe169a5' target=_blank style='color:#2F92EE;'>#export#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7169, encryptionId=64fbe169a5, topicName=export)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Mon Aug 24 12:45:00 CST 2015, time=2015-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917134, encodeId=ca12191e1348a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Feb 14 09:45:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766932, encodeId=4d7d1e669322d, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Mon Sep 28 10:45:00 CST 2015, time=2015-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314625, encodeId=4ed01314625ad, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Mar 08 00:45:00 CST 2015, time=2015-03-08, status=1, ipAttribution=)]
    2015-08-24 changfy

    #export#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1783004, encodeId=8fc71e8300410, content=<a href='/topic/show?id=854546080a' target=_blank style='color:#2F92EE;'>#chemistry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4608, encryptionId=854546080a, topicName=chemistry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Tue Oct 27 06:45:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785933, encodeId=29f11e8593335, content=<a href='/topic/show?id=64fbe169a5' target=_blank style='color:#2F92EE;'>#export#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7169, encryptionId=64fbe169a5, topicName=export)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Mon Aug 24 12:45:00 CST 2015, time=2015-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917134, encodeId=ca12191e1348a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Feb 14 09:45:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766932, encodeId=4d7d1e669322d, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Mon Sep 28 10:45:00 CST 2015, time=2015-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314625, encodeId=4ed01314625ad, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Mar 08 00:45:00 CST 2015, time=2015-03-08, status=1, ipAttribution=)]
    2016-02-14 sunylz

    #Bio#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1783004, encodeId=8fc71e8300410, content=<a href='/topic/show?id=854546080a' target=_blank style='color:#2F92EE;'>#chemistry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4608, encryptionId=854546080a, topicName=chemistry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Tue Oct 27 06:45:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785933, encodeId=29f11e8593335, content=<a href='/topic/show?id=64fbe169a5' target=_blank style='color:#2F92EE;'>#export#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7169, encryptionId=64fbe169a5, topicName=export)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Mon Aug 24 12:45:00 CST 2015, time=2015-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917134, encodeId=ca12191e1348a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Feb 14 09:45:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766932, encodeId=4d7d1e669322d, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Mon Sep 28 10:45:00 CST 2015, time=2015-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314625, encodeId=4ed01314625ad, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Mar 08 00:45:00 CST 2015, time=2015-03-08, status=1, ipAttribution=)]
    2015-09-28 12498ebem31暂无昵称

    #Biol#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1783004, encodeId=8fc71e8300410, content=<a href='/topic/show?id=854546080a' target=_blank style='color:#2F92EE;'>#chemistry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4608, encryptionId=854546080a, topicName=chemistry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Tue Oct 27 06:45:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785933, encodeId=29f11e8593335, content=<a href='/topic/show?id=64fbe169a5' target=_blank style='color:#2F92EE;'>#export#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7169, encryptionId=64fbe169a5, topicName=export)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Mon Aug 24 12:45:00 CST 2015, time=2015-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917134, encodeId=ca12191e1348a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Feb 14 09:45:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766932, encodeId=4d7d1e669322d, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Mon Sep 28 10:45:00 CST 2015, time=2015-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314625, encodeId=4ed01314625ad, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Mar 08 00:45:00 CST 2015, time=2015-03-08, status=1, ipAttribution=)]
    2015-03-08 sunylz

    #抗癌药#

    0

相关资讯

卫材抗癌药Halaven III期非小细胞肺癌失败（Study 302试验）

卫材（Eisai）8月8日公布了抗癌药物Halaven（eribulin mesylate）III期研究（Study 302）的积极顶线数据。Study 302是一项全球、多中心、随机、开放标签III期研究，在540例既往接受过至少2种晚期治疗方案（包括含铂化疗方案）但病情继续恶化的晚期非小细胞肺癌（NSCLC）患者中开展，研究中将Halaven与医生选择（TPC）的单个药物（多西他赛，培美曲

吉利德重磅药物Zydelig治疗复发性CLL III期研究疗效获突破

吉利德（Gilead）7月23日宣布，抗癌药Zydelig（idelalisib）获FDA批准，用于3种B细胞血癌的治疗，分别为：（1）批准Zydelig联合罗氏（Roche）抗癌药美罗华（Rituxan，通用名：rituximab，利妥昔单抗），用于适合Rituxan单药疗法的复发性慢性淋巴细胞白血病（CLL）患者的治疗；（2）批准Zydelig作为单药疗法，用于既往接受过至少2种系统治疗方

进口抗癌药格列卫成天价 特殊环境催高药价

“我们就是想有尊严地活下去。”慢粒白血病患者陆勇感慨。“无论富有还是贫穷，人都能在自如支配自己钱财的情况下看得起病，就是有尊严地活着。” 近日，白血病患者从印度代购仿制药格列卫的事件呈现在公众面前。尽管印度仿制药在中国没有得到认证，但是它与进口抗癌药的巨大差价让代购这条快捷途径显得颇受欢迎。 在众多讨论后，高价“救命药”背后一系列问题浮出水面：中国的进口抗癌药在众多国家中居于最高位，甚至与韩国

抗生素还是抗癌药？Pharmacyclics温馨提示

【新闻事件】：今天只有布鲁顿酶抑制剂Ibrutinib一个产品的Pharmacyclics宣布将插上草标出售自己，标价170-180亿美元。Ibrutinib去年这个时候上市，已经有四个批准适应症，去年销售为约5亿美元。今年估计能有超过10亿美元的销售，到2018年可达40亿美元。现在Pharmacyclics的市值是150亿美元。其合作伙伴强生和抗癌大佬诺华据说是潜在买主。 【药源解析】：

抗癌药物研发：在失败中涅槃

包括免疫疗法在内的新一代癌症治疗方案可谓卓越非凡，但这一进步绝非一蹴而就，期间几多波折，也只有各大药物研发机构心中自知。本文以黑色素瘤、肺癌、脑癌三项癌症为例，向您展示，在众多失败的研究为奠基的基础上，癌症治疗及药物研发领域所取得的进展。 包括免疫疗法在内的新一代癌症治疗方案可谓卓越非凡，但这一进步绝非一蹴而就，期间几多波折，也只有各大药物研发机构心中自知。一项新药在获批的道路上，注定有千万

勃林格启动抗癌药nintedanib结直肠癌全球III期研究

勃林格殷格翰（BI）近日宣布，启动一项全球III期研究，调查实验性抗癌药物nintedanib用于晚期结直肠癌（CRC）的治疗。 结直肠癌是全球第三大常见癌症，每年增加140万新发病例。晚期结直肠癌患者的预后很差，确诊后5年存活率小于10%。nintedanib是一种口服三联血管激酶抑制剂，目前，勃林格正在多种实体瘤中评价nintedanib。在美国，FDA于今年10月批准nintedanib用

Baidu
map
Baidu
map
Baidu
map